Pfizer to discontinue twice-daily weight loss pill due to high rates of adverse side effects
Pfizer said it still plans to release phase two trial data on a once-a-day version of its weight loss drug, known as danuglipron, in the first half of 2024.
Similar Posts
OpenAI appoints new boss as Sam Altman joins Microsoft in Silicon Valley twist
Post Content Post Views: 86
Shares rally as investor confidence in Fed cuts grows
Post Content Post Views: 75
Barred Venezuela candidates can take cases to tribunal, partially meeting US demands
Post Content Post Views: 79
Bitcoin derivatives traders target $40K BTC price now that Binance is resolved
Post Content Post Views: 78
Black Friday shoppers spent a record $9.8 billion in U.S. online sales, up 7.5% from last year
Black Friday kept the momentum going from the day before on Thanksgiving when online sales totaled $5.6 billion. Post Views: 76
Faraday Future Intelligent Electric expands to Middle East market
Post Content Post Views: 66